Maximizing the therapeutic potential of HSP90 inhibitors
Date
2015
Authors
Butler, L.
Ferraldeschi, R.
Armstrong, H.
Centenera, M.
Workman, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Molecular Cancer Research, 2015; 13(11):1445-1451
Statement of Responsibility
Lisa M. Butler, Roberta Ferraldeschi, Heather K. Armstrong, Margaret M. Centenera, and Paul Workman
Conference Name
Abstract
HSP90 is required for maintaining the stability and activity of a diverse group of client proteins, including protein kinases, transcription factors, and steroid hormone receptors involved in cell signaling, proliferation, survival, oncogenesis, and cancer progression. Inhibition of HSP90 alters the HSP90-client protein complex, leading to reduced activity, misfolding, ubiquitination, and, ultimately, proteasomal degradation of client proteins. HSP90 inhibitors have demonstrated significant antitumor activity in a wide variety of preclinical models, with evidence of selectivity for cancer versus normal cells. In the clinic, however, the efficacy of this class of therapeutic agents has been relatively limited to date, with promising responses mainly observed in breast and lung cancer, but no major activity seen in other tumor types. In addition, adverse events and some significant toxicities have been documented. Key to improving these clinical outcomes is a better understanding of the cellular consequences of inhibiting HSP90 that may underlie treatment response or resistance. This review considers the recent progress that has been made in the study of HSP90 and its inhibitors and highlights new opportunities to maximize their therapeutic potential.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2015 American Association for Cancer Research